D-0290-2021 Class II Terminated
FDA drug recall D-0290-2021 was initiated by Aurobindo Pharma USA Inc. on Jan 20, 2021 and is designated Class II. Reason for recall: Presence of foreign tablets/capsules: Famotidine 20mg and ibuprofen 400mg tablets were found in a lot of famotidine 40mg. The recall status is terminated (terminated Oct 12, 2023). Affected quantity: 1296 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Mar 10, 2021
- Initiation Date
- Jan 20, 2021
- Termination Date
- Oct 12, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 1296 bottles
Product description
Famotidine Tablets USP 40mg, 1,000-count bottles, Rx only, Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520 Made in India, NDC 65862-860-99
Reason for recall
Presence of foreign tablets/capsules: Famotidine 20mg and ibuprofen 400mg tablets were found in a lot of famotidine 40mg.
Distribution pattern
TX, CA, GA, PA
Code information
Lot #: P2000467, Exp 7/2022
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0290-2021
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026